drugset / Trial / NCT01318096
Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
In this pilot study, the investigators would examine the safety and efficacy of integrase inhibitor-Raltegravir in the control of HIV/HBV co-infection.
Timeline
- Start
- 2011-03
- Primary completion
- 2012-07
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Efavirenz | Other / unclassified | 600 mg | — |
| Subject | Raltegravir | Other / unclassified | 400 mg | — |
| Background | Lamivudine | Other / unclassified | 300 mg | — |
| Background | Tenofovir | Small molecule | 300 mg | — |